Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women

Journal of Infectious Diseases

Volumn 190, Issue 9, 2004, Pages 1575-1585

  Gagnon, Simon ^a,c   Hankins, Catherine ^d,e   Tremblay, Cécile ^b,c   Forest, Pierre ^a   Pourreaux, Karina ^d   Coutlée, François ^a,b,c,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CELL COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNOLOGY; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENITAL TRACT INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS 35; HUMAN PAPILLOMAVIRUS TYPE 33; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SEXUAL BEHAVIOR; STATISTICAL SIGNIFICANCE; VIRUS TYPING; WART VIRUS;

EID: 6944246229     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/424854     Document Type: Article

References (47)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
3. Chan S-Y, Bernard H-U, Ong C-K, Chan S-P, Hofmann B, Delius H. Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. J Virol 1992; 66:5714-25.
4. Coutlée F, Hankins C, Lapointe N, et al. Comparison betwen vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. J Med Virol 1997; 51:42-7.
5. Giannoudis A, Herrington CS. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001; 193:295-302.
6. Villa LL, Sichero L, Rahal P, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000; 81:2959-68.
7. Stewart AC, Eriksson AM, Manos MM, et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol 1996; 70:3127-36.
8. Aho J, Hankins C, Tremblay C, et al. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J Infect Dis 2003; 188:1517-27.
9. Xin CY, Matsumoto K, Yoshikawa H, et al. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 2001; 170:19-24.
10. Chan KS, Lam C-W, Cheung TK, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002; 94:1249-53.
11. Calleja-Macias IE, Kalantari M, Huh J, et al. Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 2004; 319:315-23.
12. Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. CMAJ 1999; 160:185-91.
13. Hankins C, Lapointe N, Walmsley S. Participation in clinical trials among women living with HIV in Canada. The Canadian Women's HIV Study Group. CMAJ 1998; 159:1359-65.
14. Coutlée F, Gravitt P, Richardson H, et al. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. J Clin Microbiol 1999; 37:1852-7.
15. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-40.
16. Cole ST, Streek RE. Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer. J Virol 1986; 58:991-5.
17. Marich JE, Ponsler AV, Rice SM, McGraw KA, Dubemsky TW. The phylogenetic relationship and complete nucleotide sequence of human papillomavirus type 35. Virology 1992; 186:770-6.
18. Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71:2463-72.
19. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22:4673-80.
20. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucl Acids Res 1998; 26:362-7.
21. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-14.
22. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-90.
23. Munger K, Scheffner M, Huibregste JM, Howley PM. Interactions of HPV type 16 oncoproteins with tumour suppressor gene products. Cancer Surv 1992; 12:197-217.
24. Werness BA, Munger K, Howley PM. Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. In: de Vita, Hellman, Rosenburg, eds. Important advances in oncology. New York: Academic Press, 1991:3-18.
25. Myers GB, Bernard H-U, Delius H, et al. Human papillomavirus: a compilation of analysis of nucleic acid and amino acid sequences [LA-UR 95-3675]. Los Alamos, NM: Los Alamos National Laboratory, 1995.
26. Crook T, Vousden KH. Interaction of HPV E6 with p53 and associated proteins. Biochem Soc Trans 1994; 22:52-5.
27. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995; 269:529-31.
28. Farthing AJ, Vousden KH. Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol 1994; 2:170-4.
29. Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994; 68:5698-705.
30. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991; 67:547-56.
31. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990; 9:153-60.
32. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type E7 gene encodes transactivation and transformation functions similar to those of adenovirus EIA. Cell 1988; 53:539-47.
33. Heinzel PA, Chan SY, Ho L, et al. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J Clin Microbiol 1995; 33:1746-54.
34. Ong CK, Chan SY, Campo MS, et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993; 67:6424-31.
35. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67:6413-23.
36. Benoist C, Chambon P. In vivo sequence requirements of the SV40 early promotor region. Nature 1981; 290:304-10.
37. Seif I, Khoury G, Dhar R. The genome of human papovavirus BKV. Cell 1979; 18:963-77.
38. Gruss P, Dhar R, Khoury G. Simian virus 40 tandem repeated sequences as an element of the early promoter. Proc Natl Acad Sci USA 1981; 78:943-7.
39. Nakagoshi H, Nagase T, Kanei-Ishii C, Ueno Y, Ishii S. Binding of the c-myb proto-oncogene product to the simian virus 40 enhancer stimulates transcription. J Biol Chem 1990; 265:3479-83.
40. Mayrand MH, Coutlee F, Hankins C, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000; 38:3388-93.
41. Nindl I. HPV variants and risk of cervical cancer. Papillomavirus Report 2002; 13:1-6.
42. Aho J, Hankins C, Tremblay C, et al. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004; 190:46-52.
43. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996; 69:364-8.
44. Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93:315-8.
45. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM. Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J Infect Dis 2002; 185:1229-37.
46. Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus types 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997; 89:796-802.
47. Xi LF, Critchlow CW, Wheeler CM, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 1998; 58:3839-44.